Pharma News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Scientists found the drug was effective in two different strains of mice and three different strains of flu believe the drug could be effective in animals other than mice, including humans. Scientists in Canada  developed a new drug that are effective against flu virus.People who die from the flu actually die from respiratory failure, when the lung's tiny blood vessels start leaking fluid into the lung's air sacs. Instead of targeting the virus that causes flu, the new drug can prevent the blood vessels from leaking fluid into the lung's air sacs.

  • ILife Discoveries, genetics and genomics company has introduced a new gene test in India. This will help oncologists get a deeper insight into tumors. The new MammaPrint & Blueprint test is able to analyse molecular subtypes of the cancer, risk of recurrence of early stage cancer, thereby enabling medical oncologists to take informed decisions on the course of treatment. For millions of breast cancer patients in India, the twin technologies are advancements that can shed new light on whether treatment is possible without undergoing the harsh chemotherapy process.

  • Hepatitis B virus is a leading cause of liver disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is a major global health problem.  A new study has found that an antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV). The study is published in Clinical Gastroenterology and Hepatology.

    [adsense:336x280:8701650588]

  • The US FDA has granted approval to Cipla's Lopinavir, Ritonavir (LPV/r) 40mg/ 10 mg oral pellets for paediatric specific treatment of HIV in infants. Cipla was working for many years in collaboration with Diana Gibb, professor of epidemiology, senior programme leader and honorary consultant paediatrician at Medical Research Council Clinical Trials Unit at UCL (University College London) towards development of this novel child-friendly formulation which has been approved by US FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. This product is a first step in making accessible more modern and appropriately formulated treatment available to the most vulnerable of HIV patients – young children.

  • The Indian Council on Medical Research (ICMR) and the National Institutes of Health (NIH), US, will soon begin collaborative research on ‘Prevention of Sexually Transmitted Diseases & HIV/AIDS’.  The joint research programme will also have thrust on HIV and AIDS-associated co-morbidities. Under this, the focus will be on utilsation of new/enhanced therapeutics for HIV-related co-morbidities such as HCV and their impact on disease outcomes; and enhanced targeted outreach strategies for HCV testing, prevention, and treatment/care engagement; integrated approaches for addressing the complex bio-behavioral factors associated with HCV/HIV. In this regard a joint Indo-US workshop is proposed to be held in September 2015 to encourage investigators for the Indo-US collaborative projects. Under translational research, the focus will be on studies to develop and test innovative HIV prevention strategies in young populations, particularly  adolescents; and also on studies to better understand linkages between reproductive health options and HIV infection in men and women.

  • A new research claims, the high level of zinc in the body may contribute to kidney stone formation. Zinc is key nutrient that is required for body. It may be the core by which stone formation starts, showed the results that might ultimately lead to the identification of new preventive and therapeutic approaches for urinary stone and diseases related to it. The study appeared in the scientific journal PLOS ONE.

  • BioCision is a leading supplier of cell cryopreservation products, systems, and solutions announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), for development of a cell thawing solution based on BioCision’s proprietary ThawSTAR technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

Subscribe to Pharma News